(Q50571205)

English

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

scientific article published in October 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

15

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Markus Schwaiger

object named as

Markus Schwaiger

6

0 references

Juliane Halangk

14

object named as

Juliane Halangk

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

13

object named as

Viola Weich

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

author name string

Martin Schaefer

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Axel Hinzpeter

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Ariane Mohmand

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Gesa Janssen

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Maurice Pich

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Rahul Sarkar

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Astrid Friebe

8

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Andreas Heinz

9

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Michael Kluschke

10

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Marlene Ziemer

11

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Juri Gutsche

12

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

language of work or name

0 references

publication date

1 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

46

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

991-998

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

Hepatitis C virus: epidemiology and transmission

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of hepatitis C in the United States.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of hepatitis C among psychiatric patients in the public sector.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of hepatitis C virus infection among injecting drug users in Australia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha (IFNalpha) and psychiatric syndromes: a review

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychiatric complications of long-term interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Interf eron-α as Adjuvant Treatment in Chronic Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21791

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.21791

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17668880

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50571205&oldid=2032501388"